FDA Classifies Vaginitis Germ Detection Device as Safe
Published Date: 8/21/2025
Rule
Summary
The FDA is officially putting a new test that spots germs causing vaginitis and bacterial vaginosis into a safer, middle-level category called Class II. This means the device will follow special safety rules, making sure it works well and is safe to use. This change helps patients get better access to these helpful tests faster, without extra red tape, and it affects companies making or selling these devices starting now.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Vaginitis/BV Test Reclassified to Class II
The FDA has classified tests that detect nucleic acid sequences from microorganisms associated with vaginitis and bacterial vaginosis into Class II (special controls). The Agency says this classification provides a reasonable assurance of safety and effectiveness and will enhance patients' access to these tests by reducing regulatory burdens.
Reduced Regulatory Burden for Manufacturers
The FDA's reclassification of the nucleic-acid test for vaginitis and bacterial vaginosis to Class II is intended to reduce regulatory burdens on makers and sellers of these devices. The rule affects companies making or selling these devices starting now according to the order.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16959, Frequently Asked Questions-Developing Potential Cellular and Gene Therapy Products; Final Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Frequently asked Questions--Developing Potential Cellular and Gene Therapy Products." The guidance document provides industry with answers to frequently asked questions (FAQs) and commonly faced issues that arise during the development of cellular and gene therapy (CGT) products. The FAQs represent common questions directed to the Agency and span multiple disciplines, including regulatory review; chemistry, manufacturing, and controls (CMC); pharmacology/toxicology; clinical; and clinical pharmacology. This guidance announced in this notice finalizes the draft guidance of the same title issued on November 19, 2024.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
Previous / Next Documents
Previous: 2025-16008, Rescinding Regulations on Procedures for Advance Construction of Federal-Aid Projects
The government is scrapping an old rule from 1990 about how federal money can be used early for big construction projects. This change affects anyone working on federal-aid road projects by making the process simpler and clearer. No new costs or deadlines pop up, but it clears the way for smoother project planning and funding.
Next: 2025-16031, Medical Devices; Immunology and Microbiology Devices; Classification of the Anti-Phospholipase A2 Receptor Immunological Test System
The FDA is officially putting the anti-phospholipase A2 receptor test into a special safety category called Class II. This means the test will have clear rules to keep it safe and effective, helping patients get access to this important medical tool faster. Labs and device makers should get ready for these new rules, which aim to make things smoother without extra costs or delays.